The Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) protocol 06 SIRveNIB randomised controlled study of SIR-Spheres Y-90 resin microspheres versus sorafenib in the treatment of unresectable primary liver cancer (hepatocellular carcinoma or HCC) has completed its target enrolment of at least 360 patients.
The US Food and Drug Administration (FDA) has finalised its efforts to streamline the “compassionate use” process, used by physicians to access investigational drugs and biologics for patients with limited treatment options.
A new bill introduced to the US Senate by Senator Dan Coats seeks to address the gap between the US Food and Drug Administration (FDA)’s priority review process for breakthrough medical devices, and the Centers for Medical and Medicare Services’ (CMS) review system for reimbursement.
Sirtex has announced that Discovery Health, a South African private health insurer, has agreed to reimburse Sir-Spheres Y-90 resin microspheres for the treatment of all forms of inoperable liver tumours. Sir-Spheres Y-90 resin microspheres are a medical device used in an interventional radiology procedure known as SIRT or radioembolisation, which targets high doses of radiation directly to liver tumours.
Lombard Medical, has announced the 30-day clinical results from 57 patients that were implanted with the Altura endograft system. The 57 patients were implanted by Albrecht Krämer at the Pontificia Universidad Católica de Chile Hospital in Santiago, Chile, and Dainis Krievins, professor and department head of Vascular and Endovascular Surgery at the Pauls Stradins Clinical University Hospital in Riga, Latvia.
What if physicians could perform an optical biopsy (defined by Thomas D Wang, associate professor, Gastroenterology, University of Michigan, USA, as one that uses the properties of light to enable the operator to make an instant diagnosis at endoscopy)? Further, what if during a cryoablation procedure, an interventional radiologist can actually see what happens during the procedure at a cellular level in real time? A new tool, Cellvizio (Mauna Kea) does just that.
A study conducted at St Thomas’ Hospital, London, UK, indicates that the VeinCLEAR catheter (RF Medical) produces good results when used in radiofrequency ablation in the treatment of lower extremity superficial venous insufficiency. The study team, led by Adam M Gwozdz, now suggest that “Long-term evaluation of this device is now needed to ensure that these encouraging early results are maintained.”
Ethicon has announced a definitive agreement to acquire NeuWave Medical. Financial terms of the transaction have not been disclosed.
Auris Surgical Robotics and Hansen Medical today announced that they have signed a definitive merger agreement under which Auris will acquire Hansen Medical for US$4.00 per share in cash, or a total equity value of approximately US$80 million.
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The combined company will thus produce devices across cardiovascular, diabetes, vision and neuromodulation markets.
Following a 2014 multicentre survey of members aiming to identify any gaps in the status of interventional radiology staffing, the Society of Interventional Radiology (SIR) has published 11 new recommendations to help centres meet the growing demand for services.
BTG has entered into an agreement to acquire Galil Medical, a provider of cryoablation products for the treatment and palliative care of kidney and other cancers.
Since its introduction in the late 80s, endovascular therapy has become increasingly widespread and important. A mini-symposium held at the 2016 Charing Cross Symposium (26–29 April, London, UK), brought to the fore the radiation damage that has occurred to pioneering operators in the field. It also focused on currently available methods to reduce radiation exposure during endovascular procedures.
Oncolytic immunotherapy or virotherapy is not a threat to interventional oncology—on the contrary it is a “huge and urgent” opportunity, said Daniel Sze while delivering the GEST USA Honorary Lecture. He spoke on the topic “Oncolytic virotherapy: A new class of agents to treat cancer.”
The results from a small prospective, randomised single-centre trial, the PREMIERE trial, show that in patients with unresectable hepatocellular carcinoma, there is a significantly longer time to progression with yttrium-90 (Y-90) radioembolization than with conventional transarterial chemoembolization (cTACE).
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos